Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Radiation Oncology
•
Myelodysplastic Syndromes
•
Hematology
What are your current recommendations for treatment of symptomatic splenomegaly in the setting of myelofibrosis when splenectomy is not an option?
Is there a preferred low dose splenic irradiation regimine?
Answer from: Radiation Oncologist at Academic Institution
I use low dose, typically 50cGy per fraction for 4-6 fractions, done in 2 fractions per week; need to check platelets each week during course.
Sign in or Register to read more
881
Related Questions
For plasmablastic lymphoma responsive to treatment except for a recurrent lymph node eroding into a vertebral body at the end of chemotherapy, would you cover the entire vertebral body in your CTV, or treat only the involved lymph node with a margin?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
How would you approach transfusion-dependent anemia in an intermediate-risk MDS patient refractory to azacitidine?
What is the risk of radiation therapy to an abdominal aortic aneurysm infiltrated by lymphoma?
How do you approach management for CCUS with severe cytopenias?
What radiation treatment volume and dose would you deliver to an isolated DLBCL relapse in the left eye s/p vitrectomy and intraocular methotrexate?
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
What is your approach to managing follicular lymphoma with central nervous system involvement?
In the post Covid era, could the ILROG hypofractionated regimens (published as "emergency guidelines" for lymphoma) be considered as standard of care for ISRT?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?